Ischaemic heart disease presenting as arrhythmias

British Medical Bulletin

Volumn 59, Issue , 2001, Pages 193-210

  Ghuran, A V ^a   Camm, A J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; HYPOCHOLESTEROLEMIC AGENT; LIDOCAINE; METOPROLOL; PROCAINAMIDE; PROPRANOLOL; VERAPAMIL;

ACTION POTENTIAL; ARRHYTHMOGENESIS; AUTONOMIC NERVOUS SYSTEM FUNCTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG INDICATION; EXTRACELLULAR FLUID; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

ANTICOAGULANTS; ARRHYTHMIA; AUTONOMIC NERVOUS SYSTEM; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HEART; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 0035685880     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/59.1.193     Document Type: Review

References (50)

1. Clinical epidemiology of coronary heart disease in the UK
2. Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis
3. The autonomic nervous system and sudden death
4. Rapid activation of the sympathetic nervous system following coronary artery occlusion: Relationship to infarct size, site, and haemodynamic impact
5. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
6. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction
7. Ventricular arrhythmias in ischemic heart disease: Mechanism, prevalence, significance, and management
8. Five hundred patients with myocardial infarction monitored within one hour of symptoms
9. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results
10. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
11. Mortality and morbidity in patients receiving encainide, flecainide, or placebo
12. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials
13. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators
14. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial
15. Primary ventricular tachycardia in acute myocardial infarction: Clinical characteristics and mortality
16. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence
17. Ectopic ventricular prematurity and its relationship to ventricular tachycardia in acute myocardial infarction in man
18. Non-sustained ventricular tachycardia in the setting of acute myocardial infarction: Tachycardia characteristics and their prognostic implications
19. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up
20. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction
21. Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases
22. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators
23. A randomized study of the prevention of sudden death in patients with coronary artery disease
24. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction
25. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
26. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction
27. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia
28. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia
29. Intravenous antiarrhythmic therapy for high-risk patients
30. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support: 7D: The tachycardia algorithms
31. Polymorphous ventricular tachycardia associated with acute myocardial infarction
32. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study
33. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
34. Treating electrical storm: Sympathetic blockade versus advanced cardiac life support-guided therapy
35. Radiofrequency ablation of haemodynamically unstable ventricular tachycardia after myocardial infarction
36. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
37. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation)
38. Coronary artery revascularisation in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: Effects on the electrophysiologic substrate and outcome
39. Surgical coronary revascularization in survivors of prehospital cardiac arrest: Its effect on inducible ventricular arrhythmias and long-term survival
40. Atrial tachyarrhythmias in acute myocardial infarction
41. Early atrial fibrillation during evolving myocardial infarction: A consequence of impaired left atrial perfusion
42. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
43. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction
44. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study
45. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial
46. Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: A reappraisal in the thrombolytic era
47. Early and late atrioventricular block in acute inferior myocardial infarction
48. Acute myocardial infarction
49. Intraventricular conduction defects in acute myocardial infarction: Incidence, prognosis, and therapy
50. American College of Cardiology/American Heart Association guidelines for pacemaker implantation after acute myocardial infarction. What is persistent advanced block at the atrioventricular node?